The ROE as of November 2024 (TTM) for Ionis Pharmaceuticals, Inc. (IONS) is -89.18%

According to Ionis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -89.18%. This represents a change of 268.17% compared to the average of -24.22% of the last 4 quarters.

Ionis Pharmaceuticals, Inc. (IONS) Historical ROE (quarterly & annually)

How has IONS ROE performed in the past?

The mean historical ROE of Ionis Pharmaceuticals, Inc. over the last ten years is -30.51%. The current -89.18% ROE has changed 192.31% with respect to the historical average. Over the past ten years (40 quarters), IONS's ROE was at its highest in in the December 2018 quarter at 30.54%. The ROE was at its lowest in in the June 2016 quarter at -51.12%.

Ionis Pharmaceuticals, Inc. (IONS) ROE by Quarter and Year

Discovering the peaks and valleys of Ionis Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ionis Pharmaceuticals, Inc. (IONS) Average ROE

How has IONS ROE performed in the past?

The current ROE of Ionis Pharmaceuticals, Inc. (IONS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Ionis Pharmaceuticals, Inc. (IONS) ROE vs. Peers

How is IONS’s ROE compared to its peers?

Ionis Pharmaceuticals, Inc.’s ROE is less than Arrowhead Pharmaceuticals, Inc. (0%), greater than BioMarin Pharmaceutical Inc. (-172.90%), less than Incyte Corporation (6.22%), less than Apellis Pharmaceuticals, Inc. (0.78%), greater than Viking Therapeutics, Inc. (-103.92%), greater than Intercept Pharmaceuticals, Inc. (-12.73%), greater than Terns Pharmaceuticals, Inc. (-12.41%), greater than Akero Therapeutics, Inc. (-32.76%), greater than Reata Pharmaceuticals, Inc. (-32.52%), less than Seagen Inc. (47.21%), greater than Alnylam Pharmaceuticals, Inc. (-16.53%), less than Exelixis, Inc. (323.66%), less than Halozyme Therapeutics, Inc. (21.26%), less than PTC Therapeutics, Inc. (156.40%), less than Krystal Biotech, Inc. (48.38%), less than Sarepta Therapeutics, Inc. (6.34%), less than Iovance Biotherapeutics, Inc. (11.83%), greater than Madrigal Pharmaceuticals, Inc. (-58.43%), greater than null (-71.78%),

Build a custom stock screener for Ionis Pharmaceuticals, Inc. (IONS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ionis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ionis Pharmaceuticals, Inc. (IONS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ionis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.